A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Completed · Phase 1 · Has a placebo group

Conditions studied: Diabetes Mellitus Type 2

In brief

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Successive cohorts of patients will be randomized to receive either active drug, at escalating doses, or placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.

Key facts

Study ID

NCT00682097

Run by

Hoffmann-La Roche

People needed

55

Starts

2008-05-01

Expected to finish

2009-03-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients, 18-65 years of age;
• type 2 diabetes;
• either treated by diet and exercise alone or with metformin.

You may not qualify if…

• type 1 diabetes mellitus;
• uncontrolled hypertension;
• clinically severe diabetic complications.

Where it is running

• Study site — Chula Vista, California, United States
• Study site — San Antonio, Texas, United States
• Study site — Neuss, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.